# Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

> **NCT04138706** · PHASE3 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 263 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** Vancomycin
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04138706
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-19
- **Primary completion:** 2024-10-04
- **Final completion:** 2024-11-22
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138706, "Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04138706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*